Why the study?
Is replacing NSAIDs with cyclooxygenase-2 inhibitors cost-effective in patients with rheumatoid arthritis?
Is replacing NSAIDs with cyclooxygenase-2 inhibitors cost-effective in patients with rheumatoid arthritis?
This cost-effectiveness analysis explores the economic factors and relevant patient groups for prescribing coxibs over traditional NSAIDs in Norway.
May support targeted coxib use in select RA patients; leaves open broader cost-effectiveness in observational data.
Cyclooxygenase-2 inhibitors exhibit the same effectiveness on rheumatic symptoms as nonsteroidal anti-inflammatory drugs, have fewer gastrointestinal side effects, but a higher price. Based on cost and healthcare utilization in Norway, this paper explores what factors are most important for the cost-effectiveness of cyclooxygenase-2 inhibitors and points to patient groups that may be most relevant for prescribing coxibs instead of nonsteroidal anti-inflammatory drugs.
No takes yet. Share an insight, caveat, or question.
Kristiansen et al. (2002) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: